Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses (Q43477258)

23 November 2017

Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses (English)

1 reference

23 November 2017

7

Robin J Shattock

1 reference

23 November 2017

Christelle Liard

1

1 reference

23 November 2017

Séverine Munier

2

1 reference

23 November 2017

Mauricio Arias

3

1 reference

23 November 2017

Alix Joulin-Giet

4

1 reference

23 November 2017

Olivia Bonduelle

5

1 reference

23 November 2017

Darragh Duffy

6

1 reference

23 November 2017

Bernard Verrier

8

1 reference

23 November 2017

Behazine Combadière

9

1 reference

23 November 2017

language of work or name

English

0 references

publication date

7 May 2011

1 reference

23 November 2017

1 reference

23 November 2017

29

1 reference

23 November 2017

37

1 reference

23 November 2017

6379-6391

1 reference

Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.

23 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

"Dermal dendritic cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Resident and "inflammatory" dendritic cells in human skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Particle-based vaccines for transcutaneous vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Immunization without needles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Mature Human Langerhans Cells Derived from CD34+ Hematopoietic Progenitors Stimulate Greater Cytolytic T Lymphocyte Activity in the Absence of Bioactive IL-12p70, by Either Single Peptide Presentation or Cross-Priming, Than Do Dermal-Interstitial or

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Tumor immunotherapy by epicutaneous immunization requires langerhans cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Targeting to the hair follicles: current status and potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Follicular transport route--research progress and future perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Skin immunization made possible by cholera toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Targeting early infection to prevent HIV-1 mucosal transmission.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Immunology and the elusive AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Challenges in the development of an HIV-1 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Critical issues in mucosal immunity for HIV-1 vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Assessment of mucosal immunity to HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Vaccine development strategies for improving immunization: the role of modern immunology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Nanoparticles target distinct dendritic cell populations according to their size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

The 500 Dalton rule for the skin penetration of chemical compounds and drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Nanovaccines: recent developments in vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59 impacts the breadth, but not the magnitude, of serum and faecal antibody responses in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Modern mucosal vaccines, adjuvants and microbicides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Epitope mapping and affinity estimation of 83 antibodies against prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Immunology of the hair follicle: a short journey into terra incognita

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Effector and memory T-cell differentiation: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Lymphokine control of in vivo immunoglobulin isotype selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Inhibiting sexual transmission of HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Immunisation against plague by transcutaneous and intradermal application of subunit antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Transcutaneous immunization with inactivated influenza virus induces protective immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Transcutaneous immunization: a human vaccine delivery strategy using a patch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

T-cell quality in memory and protection: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

CD8+ T cell efficacy in vaccination and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

The IL4- induced switch of CD8+ T cells to a TH2 phenotype and its possible relationship to the onset of AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Original encounter with antigen determines antigen-presenting cell imprinting of the quality of the immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Bridging the knowledge gaps in vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Live attenuated versus inactivated influenza vaccine in infants and young children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Translating innate immunity into immunological memory: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Found in translation: the human equivalent of mouse CD8+ dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Nanotechnology in vaccine development: a step forward.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Dendritic cells and humoral immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Serum antibody responses after intradermal vaccination against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Safe vaccination of children with a virosomal adjuvanted influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.04.080

10.1016/J.VACCINE.2011.04.080

7 January 2021

Identifiers

DOI

1 reference

23 November 2017

1 reference